Transcarent Launches Innovative Bundled Payment Model for Breakthrough Cancer Therapies

Industry-leading Centers of Excellence solution expands access to BiTE and CAR T at more predictable costs

SAN FRANCISCO, August 25, 2026--Transcarent, the first agentic AI-powered health and care platform, today announced a first-of-its-kind bundled payment model for bispecific T-cell engager (BiTE) and CAR T therapies delivered through high-quality community providers, further enhancing their industry-leading complex care Centers of Excellence (COE) capabilities. The model enables Transcarent's Cancer Care experience to bring advanced cancer care closer to where Members live while giving employers a more predictable way to manage rising oncology costs.

Advanced therapies for specialty conditions like cancer represent some of the most significant treatment advances, particularly for patients who have exhausted other options, but they also introduce new access, cost, and care coordination challenges for employers. Innovative cancer treatments can cost hundreds of thousands of dollars and are often limited to a small number of academic medical centers, requiring patients and caregivers to travel long distances while navigating complex referrals and prior authorization requirements.

"Advanced cancer therapies are changing what's possible for patients, but they're also creating new challenges for employers trying to manage costs and access," said Snezana Mahon, PharmD, President of Transcarent. "This model gives employers more predictable costs while helping Members receive expert care closer to home without sacrificing quality."

This expansion enhances Transcarent's Centers of Excellence (COE) program by making specialty care easier to access, easier to navigate, and more affordable. Through bundled payment agreements with high-quality regional and community providers, Members can receive coordinated care with expert guidance throughout their care journey while employers get more predictable costs.

Since BiTE and CAR T therapies are used to treat a range of complex cancers and patient circumstances, the total cost of treatment can vary significantly from case to case. Transcarent connects Members to leading oncology providers across academic medical centers, NCI-Designated Cancer Centers, and high-quality community-based sites of care for complex cancer services, including surgery, radiation, infusions, and now CAR T and BiTE therapies. By expanding access to advanced immunotherapies, Transcarent's model makes it easier for people to get quality treatment closer to home and offers the potential for savings of up to $150,0001.